Systematic review of the prevalence of Mycobacterium tuberculosis resistance in Saudi Arabia
- PMID: 26179987
- DOI: 10.1179/1973947815Y.0000000058
Systematic review of the prevalence of Mycobacterium tuberculosis resistance in Saudi Arabia
Abstract
Aim: To quantitatively estimate the prevalence of resistance of Mycobacterium tuberculosis (TB) to first line agents in Saudi Arabia.
Methods: The overall prevalence of M. tuberculosis resistance was calculated using meta-analysis.
Results: We included 22 studies from Saudi Arabia that were published from 1979 to 2013.A high degree of heterogeneity among studies was observed. Based on random effect methodology, the prevalence (and 95% CI) of the resistance rates were: INH 10.13 (8.13-12.11), rifampicin 5.41 (4.21-6.61), ethambutol 1.29 (1.83-2.37) and streptomycin 6.5 (4.9-8.1), and multi-drug resistant was 6.7 (5.1-8.3).
Conclusion: The prevalence of resistance to anti-tuberculous agents was highest for INH followed by streptomycin and rifampicin. Multi-drug resistant tuberculosis remains at 6.7%. The data support the recommendations to use four anti-tuberculous agents as empiric therapy.
Keywords: Resistance; Saudi Arabia; Systematic review; Tuberculosis.
Similar articles
-
Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.BMC Infect Dis. 2017 Mar 20;17(1):219. doi: 10.1186/s12879-017-2323-y. BMC Infect Dis. 2017. PMID: 28320336 Free PMC article.
-
Resistance Rates of Mycobacterium tuberculosis Complex Strains: A Retrospective Study in Türkiye.Medicina (Kaunas). 2025 Jun 9;61(6):1060. doi: 10.3390/medicina61061060. Medicina (Kaunas). 2025. PMID: 40572748 Free PMC article.
-
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841. doi: 10.1002/14651858.CD014841.pub2. Cochrane Database Syst Rev. 2022. PMID: 35583175 Free PMC article.
-
Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.BMC Public Health. 2015 Mar 25;15:291. doi: 10.1186/s12889-015-1614-8. BMC Public Health. 2015. PMID: 25880829 Free PMC article.
-
Mutations associated with resistance to rifampicin and isoniazid identified in strains of the Mycobacterium tuberculosis complex by GenoType MTBDRplus in Panama, 2015-2021.Microbiol Spectr. 2025 Jul;13(7):e0240024. doi: 10.1128/spectrum.02400-24. Epub 2025 Jun 9. Microbiol Spectr. 2025. PMID: 40488462 Free PMC article.
Cited by
-
Ending tuberculosis in Gulf Cooperation Council countries: an overview of the WHO End TB Strategy 2025 milestones.IJID Reg. 2025 Jun 6;16:100681. doi: 10.1016/j.ijregi.2025.100681. eCollection 2025 Sep. IJID Reg. 2025. PMID: 40678394 Free PMC article. Review.
-
Successful treatment of extra-pulmonary tuberculosis presenting concomitantly with acute myeloid leukemia.Infection. 2019 Oct;47(5):869-874. doi: 10.1007/s15010-019-01334-1. Epub 2019 Jun 24. Infection. 2019. PMID: 31236899
-
Middle East respiratory syndrome coronavirus in the last two years: Health care workers still at risk.Am J Infect Control. 2019 Oct;47(10):1167-1170. doi: 10.1016/j.ajic.2019.04.007. Epub 2019 May 23. Am J Infect Control. 2019. PMID: 31128983 Free PMC article.
-
Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis.PLoS One. 2021 Oct 8;16(10):e0258295. doi: 10.1371/journal.pone.0258295. eCollection 2021. PLoS One. 2021. PMID: 34624050 Free PMC article.
-
Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.Saudi Med J. 2021 Jun;42(6):636-642. doi: 10.15537/smj.2021.42.6.20200832. Saudi Med J. 2021. PMID: 34078725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
